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Optimized Allotopic Expression of the Human
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in a Rat Model of Mitochondrial Dysfunction
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Vale´rie Forster,1 Serge Picaud,1 Jose-Alain Sahel,1 and Marisol Corral-Debrinski1,*
Mitochondrial diseases due to mutations in mitochondrial DNA can no longer be ignored in most medical areas. With prevalence cer-
tainly higher than one in 6000, they probably represent the most common form of metabolic disorders. Despite progress in identiﬁca-
tion of their molecular mechanisms, little has been done with regard to therapy.We have recently optimized the allotopic expression for
the mitochondrial genes ATP6, ND1, and ND4 and obtained a complete and long-lasting rescue of mitochondrial dysfunction in the
human ﬁbroblasts in which these genes were mutated. However, biosafety and beneﬁt to mitochondrial function must be validated
in animalmodels prior to clinical applications. To create an animalmodel of Leber Hereditary Optic Neuropathy (LHON), we introduced
the human ND4 gene harboring the G11778A mutation, responsible of 60% of LHON cases, to rat eyes by in vivo electroporation. The
treatment induced the degeneration of retinal ganglion cells (RGCs), which were 40% less abundant in treated eyes than in control eyes.
This deleterious effect was also conﬁrmed in primary cell culture, in which both RGC survival and neurite outgrowthwere compromised.
Importantly, RGC loss was clearly associated with a decline in visual performance. A subsequent electroporation with wild-type ND4
prevented both RGC loss and the impairment of visual function. Hence, these data provide the proof-of-principle that optimized allo-
topic expression can be an effective treatment for LHON, and they open the way to clinical studies on other devastating mitochondrial
disorders.Introduction
Mitochondrial diseases encompass an extraordinary
assemblage of clinical problems, commonly involving
tissues that have high energy requirements, such as retina,
brain, heart, muscle, liver, and endocrine systems. The
clinical presentations range from fatal infantile disease to
muscle weakness, andmost are characterized by inexorable
progression.1 Moreover, mitochondrial dysfunctions also
contribute directly or indirectly to tumor formation and
the aging process.1,2 Approximately 300 mtDNA alter-
ations have been identiﬁed as the genetic cause of mito-
chondrial diseases; one-third of these alterations are
located in coding genes for oxidative phosphorylation
(OXPHOS) proteins.3 Recent epidemiological studies
have shown that mtDNA-related disease prevalence is at
least one in 6000.4 The understanding of the pathogenesis
of mitochondrial diseases has improved considerably in
the last decade. Nevertheless, the most disappointing
area is the lack of efﬁcient treatments for patients with
mitochondrial diseases. Indeed, they are still treated with
vitamin and cofactor mixtures, which are harmless but
largely inadequate and inefﬁcient.5
Leber hereditary optic neuropathy (LHON [MIM
535000]) was the ﬁrst maternally inherited disease
associated with point mutations in mitochondrial DNA
(mtDNA)6 and is now considered the most common mito-
chondrial disorder, with an estimated prevalence of 1 in
25,000 in north-east England.7,8 It has recently been
reported that LHON might be responsible for as much as2% of blindness in individuals under age 65.9 The pathol-
ogy is characterized by selective death of retinal ganglion
cells (RGC) and optic nerve atrophy, leading to central vi-
sion loss. The most common pathogenic mutations found
in about 95% of LHON patients are located in ND1
(G3460A) [MIM 516000], ND4 (G11778A) [MIM 516003],
or ND6 (T14484C) [MIM 516006] genes. They encoded
subunits of the respiratory chain complex I, and the muta-
tions have the double effect of lowering ATP synthesis and
increasing oxidative stress chronically.10
For diseases caused by mutations in mtDNA, such as
LHON, allotopic expression (expression of mitochondrial
genes transferred to the nucleus) of some of them has
been tried in vitro as a potential therapeutic option.11,12
However, several attempts failed to obtain complete and
long-lasting rescue of mitochondrial defects in cultured
cells carrying mutations of mtDNA genes.13,14 We have
recently optimized the allotopic expression for the mito-
chondrial genes ATP6 [MIM 516060], ND1, and ND4 and
obtained a complete and long-term restoration of mito-
chondrial function in human ﬁbroblasts in which these
genes were mutated. This optimization was reached by
mRNA targeting to the mitochondrial surface, which lead
to a tight coupling between both translation and transloca-
tion processes; this tight coupling is required for highly
hydrophobic proteins, such as ATP6, ND1, and ND4.15,16
The next mandatory step before any attempt to clinical
application of our strategy is to provide the proof-of-
principle that our vectors are both safe and beneﬁcial to
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obstacle to this goal is the lack of a reliable animal model
faithfully recapitulating the main characteristics of human
diseases due to mtDNA mutations.5 Our aim was to create
an experimental model of LHON; therefore, we used the
optimized-allotopic-expression approach and in vivo
electroporation (ELP)17 to introduce on adult rat eyes the
human ND4 gene harboring the G11778A substitution.
This mutation, responsible for 60% of LHON cases, con-
verts a highly conserved arginine to histidine at codon
340.10 Histological evaluation of these animal retinas
showed a signiﬁcant decrease (30%–40%) in the overall
number of RGCs compared to those in animals in which
in vivo ELP was performed with either wild-type ND4 or
the green ﬂuorescence protein (GFP). The decreased num-
ber of RGCs was associated with impaired visual function.
Remarkably, RGC loss was rescued by a second ELP with
the wild-type ND4 gene and prevented a decline in visual
function. These data represent the ‘‘proof of principle’’
that optimized allotopic expression is effective in vivo
and can be envisaged as a therapy for mtDNA-related
diseases.
Material and Methods
Animals
Male Wistar and Long Evans rats (Janvier, Le Genest Saint Isle,
France) of 8–14 weeks of age (250–300 g) were housed two per
cage in a 12 hr light/12 hr dark cycle and were fed water and dried
rations ad libitium. Experiment protocols were developed in accor-
dance with the ARVO (Association for Research in Vision and
Ophthalmology) Statement for the Use of Animals in Ophthalmic
and Visual Research.
Plasmid Construction
The optimized human wild-type ND4ORF fused to the ﬁrst 84 nu-
cleotides of the human COX10 [MIM 602125] ORF was obtained
as previously described.15,16 The COX10 fragment encodes the
21 residue N-terminal mitochondrial targeting sequence (MTS)
and seven additional residues that ensure proper MTS cleavage
(MAASPHTLSSRLLTGCVGGSVWYLERRT). Using the Quick
Change Multi Site-Directed Mutagenesis Kit (Stratagene, USA)
and the primer CTACGAAAGGACACACTCACACATTATGATTCT
GAGCCAGG, we performed in vitro mutagenesis of the wild-type
engineered human ND4 gene to obtain a nuclear version harbor-
ing the G11778A substitution.
We cloned the fusion COX10-ND4 sequences into the pAAV-
IRES-hrGFP vector (Stratagene) by using BamHI and XhoI. In the
recombinant vectors three FLAG epitopes are appended in frame
to the C terminus of ND4 proteins. To obtain hybrid mRNAs
that also contained the COX10 30 UTR, we replaced the hGH (hu-
man growth hormone 1 [MIM 139250]) poly adenylation signal of
the vector with the 1425 bp full-length COX10 30 UTR by using
BglII and RsrII sites. Final constructs were sequenced for accuracy
(Genome Express, France). DNA puriﬁcations for in vivo ELP were
performed with the QIAprep Maxiprep Kit Endofree (QIAGEN) ac-
cording to the manufacturer’s instructions. DNAs were diluted in
TE buffer (10 mM Tris [pH 7.5]; 1 mM EDTA) at a ﬁnal concentra-
tion of 5 mg/ml.374 The American Journal of Human Genetics 83, 373–387, SeptemThe hrGFP gene serves as a useful marker for detecting cells
expressing the transgene. The corresponding protein is a human-
ized Renilla reniformis protein that is less toxic than the jellyﬁsh
Aequorea victoria EGFP protein. However, because the gene is lo-
cated downstream from the IRES, its expression is low, as reported
by the manufacturer. Hence, hrGFP ﬂuorescence was evaluated
with an antibody against GFP.
In Vivo Electroporation
The electroporation procedure was performed essentially as de-
scribed by Ishikawa and colleagues17 but with somemodiﬁcations.
Under anesthesia with isoﬂurane (40mg/kg body weight), 20 mg of
DNA (4 ml and 1/10 of ﬂuorescein) were injected into the vitreous
body with a 30 gauge needle 0.5 mm posterior to the limbus after
dilation of the pupil. After 5 min the contact-lens-type and needle
electrodes were positioned, and square wave pulses were delivered.
Electric pulses were generated by an Electro Square Porator (T830;
BTX, San Diego, CAUSA). Conditions were as follows: electric ﬁeld
strength of 9 V/cm, pulse duration of 100 ms, and a stimulation
pattern of ﬁve series of electric pulses with frequency of one pulse
per second, interrupted by 5 min pauses in-between. ELPs were
performed in only one eye per rat. Eye fundus images were cap-
tured the day after the procedure and before animal sacriﬁces to
ensure the technique safety. One percent of examined animals
developed cataracts and were excluded from further analyses.
RGCs were puriﬁed from 228 animals for ex vivo studies and
RT-PCR analyses. RGC counts were performed in 150 electropo-
rated animals. Retinal sections from 12 electroporated animals
were subjected to a TUNEL assay. Retinal whole mounts from
12 animals that had been subjected to in vivo ELP were processed
for immunohistochemistry with NF200. Visual performances of
46 animals subjected to ELP were monitored with an optomotor
test. Within this animal group after the animals’ sacriﬁce, 32
were used for RGC counting, 8 retinal whole mounts were
performed, and 6 retinas were subjected to TUNEL assay.
Histology and RGC Counts
Animals were sacriﬁced by transcardiac perfusion with 4% parafor-
maldehyde (PAF) under deep ketamine (50 mg/kg) and xylazine
(10 mg/kg) anesthesia. The globes were removed from the animal,
a small marking burn apart from the retina was placed on the eyes
for the identiﬁcation of retinal orientation, and the eyes were then
pierced in the cornea with a needle and ﬁxed for 1 hr in 3% PAF at
4C. After the ﬁrst ﬁxation, the cornea and lens were removed and
postﬁxed overnight in 4% PAF at 4C. Next, eyes were cryopro-
tected for 1 hr in 20% sucrose-PBS (Sigma-Aldrich) at 4C and
overnight in 30% sucrose-PBS at 4C. The next day, retinas were
embedded in OCT (Neg 50; Richard-Allan Scientiﬁc), frozen in liq-
uid nitrogen, and stored at20C. Sections (10 mm thick) were cut
on a Microm Cryostat (Microm Microtech, France) at 20C and
mounted on SuperFrost@Plus slides (Menzel-Gla¨ser, Germany).
Nine slides were obtained per eye; each slide contained six consec-
utive sections from the superior side. Because DNA injection was
performed on the superior side and the RGC population increases
near the optic nerve (ON) 18, RGC counts were performed from
each retina on four entire consecutive cryostat sections with the
same deepness at 400 mm from the ON. Cryostat sections of retinas
were washed with PBS, permeabilized with 0.1% Triton X-100 in
PBS for 5 min at room temperature, and treated with 0.1% bovine
serum albumin (BSA [Sigma-Aldrich]) and 0.1% Tween 20 in PBS
for 1 hr so that nonspeciﬁc binding sites would be blocked. Theber 12, 2008
retinas were then incubated with polyclonal rabbit antibody
against NF200 (1 mg/ml, Sigma-Aldrich) or against GFP (1.5 mg/
ml, Torrey Pines Biolabs, USA) and either monoclonal mouse anti-
body against BRN3a (1 mg/ml, Chemicon) or monoclonal FLAG
(2.5 mg/ml, F3165, Sigma- Aldrich) overnight at 4C. Next, sections
were washed three times in PBS and incubatedwith DAPI (2 mg/ml;
Sigma-Aldrich) and appropriate secondary antibodies conjugated
with monoclonal mouse 594 (4 mg/ml, Invitrogen) or goat anti-
rabbit 488 (4 mg/ml, Invitrogen) for 1.5 hr at room temperature.
We performed negative control experiments by incubating retinal
sections with each secondary antibody. Three or four persons who
were masked with regard to the identity of experimental and con-
trol eyes estimated RGC numbers with the help of Image J soft-
ware.
TUNEL Assay
Four consecutive cryostat sections corresponding to 400 mm from
the ON were chosen, and a TUNEL assay was performed with the
in situ apoptosis detection kit (Roche, Penzberg, Germany) accord-
ing to the manufacturer’s instructions. For the positive control,
the sections were treated with DNase. The number of TUNEL-
positive cells per section was obtained from the counting of colo-
calization between DAPI and TUNEL stainings. Six animals were
used for each condition.
Retinal Whole Mounts and Immunochemistry
Rat eyes were enucleated; the anterior segment, the lens, and the
vitreous bodywere rapidly removed; and eyes were ﬁxed overnight
with 4% PAF. After three washes in PBS, retinas were incubated in
3% BSA (Sigma-Aldrich) and 0.05% Tween-20 (Sigma-Aldrich) for
20 min. Next, retinas were permeabilized with 0.1% Triton X-100
for 5 min, rinsed with PBS, and incubated with polyclonal NF200
antibody (1 mg/ml, Sigma-Aldrich) overnight at 4C. After three
washes with PBS, they were treated with the secondary antibody
goat anti-rabbit 488 (4 mg/ml, Invitrogen) and DAPI (2 mg/ml,
Sigma-Aldrich) for 1.5 hr and ﬁnally washed three times in PBS.
The eye cupwas cut peripherally in four sections under a binocular
optic microscope and ﬂattened. The sclera/choroid/RPE was
removed with ﬁne forceps, and the neuroretina was mounted on
aglass slide andexaminedbyﬂuorescencemicroscopy. Twelve elec-
troporated eyes were observed and compared to four control eyes.
Puriﬁcation of RGCs for Primary Cultures
and Semiquantitative RT-PCR Analyses
Primary cell cultures were derived from adult rat retinas and puri-
ﬁed bymodiﬁcations of the sequential immunopanning described
for young rats.19 RGCs andmacrophages were resuspended in half
NBA medium (Invitrogen) supplemented with B27 (1:50; Invitro-
gen) and L-glutamine (2 mM; Invitrogen) and half rat-retinal
cell-conditioned culture medium,20 and seeding was performed
at 20,000 cells/cm2 into 48-well tissue-culture plates containing
coverslips previously coated overnight with poly-D-lysine (2 mg/
cm2 for 1 hr) and then with laminin (1 mg/cm2 overnight: both
from Sigma-Aldrich). Cells were incubated at 37C in a humidiﬁed
atmosphere of 5% CO2. Ten days later, cells were ﬁxed with 4%
PAF solution for 15 min at room temperature and washed three
times in PBS before immunocytochemistry analyses were per-
formed. Coverslips containing RGCs were permeabilized with
0.1% Triton X-100 in PBS for 5 min at room temperature and
treated with 0.1% BSA (Sigma-Aldrich) and 0.1% Tween-20
(Sigma-Aldrich) in PBS for 1 hr so that nonspeciﬁc binding sitesThe Americanwould be blocked. Then, they were incubated with polyclonal rab-
bit antibody against NF200 (1 mg/ml, Sigma-Aldrich), monoclonal
anti-ATP synthase subunit a (0.5 mg/ml, Invitrogen), or monoclo-
nal anti-FLAG M2 (2.5 mg/ml, Sigma-Aldrich) overnight at 4C.
The next day, samples were washed and treated for 1.5 hr at
room temperature with DAPI (2 mg/ml, Sigma-Aldrich) and appro-
priate secondary antibodies: labeled goat anti-mouse IgG1 Alexa
Fluor 488 for the anti-Flag M2 antibody (2 mg/ml; Invitrogen), la-
beled goat anti-rabbit IgG1 Alexa Fluor 488 (2 mg/ml; Invitrogen)
for the anti-NF200 antibody, and labeled goat anti-mouse IgG 2b
Alexa Fluor 594 (2 mg/ml, Invitrogen) for the anti-ATP synthase
subunit a antibody (Molecular Probes, Invitrogen). Cell counts
have been performed manually and as blind tests with regard to
animal identities after ﬂuorescence microscopy observations. Esti-
mations of cell body diameters and neurite lengths in cultured
RGCs were performed with the Image J software.
For RT-PCR analyses, we extracted total RNAs with the RNeasy
Protect Mini kit (QIAGEN) from 8 3 105 cells that we obtained
by pooling 18 retinas subjected to RGC puriﬁcation. RT-PCR anal-
yses were performed with the Superscript III one-step RT-PCR
Platinum Taq kit (Invitrogen). We estimated steady-state levels of
different mRNAs by using 60 ng of total RNA from RGCs puriﬁed
25 days after ELP with GFP, wild-type ND4, or mutant ND4 and
speciﬁc primers (Table S1, in the Supplemental Data available
with this article online). Twenty-ﬁve, 30, and 35 cycles of PCR am-
pliﬁcation were performed with three independent RNA puriﬁca-
tions. The intensity of PCR products was quantiﬁed with the
Quantity One 1-D Analysis Software (Bio-Rad Laboratories, USA).
Microscopic Observations
Fluorescence labeling was monitored with a ﬂuorescence micro-
scope (Leica DM 5000 B). Magniﬁcations of 2003, 4003, or
6303 were used for the acquisition of images with the MetaVue
software. The images were analyzed with Photoshop and Image J
software.
Optomotor Tests
The head-tracking method is based on an optomotor test devised
by Cowey and Franzini in 197921 and frequently used since
then.22,23 Eight-, 12-, or 14-week-old Long Evans rats were placed
individually into an enclosed clear plastic container, surrounded
by amotorized drum that could revolve clockwise or counterclock-
wise. Each animal was placed in a clear plastic stationary round
chamber at the center of the drum, which allows visualization
and exposure of both eyes to the stimulus. A single blinded oper-
ator conducted all assessments, and codes were broken upon com-
pletion of data acquisition. The operator waited for the animal to
settle in the chamber before initiating drum rotation. Vertical
black-and-white lines of three varying widths, subtending 0.125,
0.25, and 0.5 cycles/degree (cyc/deg) were presented to the animal
and rotated alternatively clockwise and counterclockwise, each for
60 s. This stimulated a subcortical reﬂex, so that a seeing animal
involuntarily turned its head to track the moving lines. Head
movements were recorded with a video camera mounted above
the apparatus. Animals were scored only when the speed of the
head turn corresponded to the speed of rotation of the stripes
(12/s). Habitual and other seemingly randomized movement
was excluded from the timing. Light levels were kept constant
(240 lux), and the plastic container was cleaned between animals.
Each animal was tested at two different time points by a single
observer. During the experiments, a second masked graderJournal of Human Genetics 83, 373–387, September 12, 2008 375
Figure 1. Efficacy of Gene Transduction for In Vivo ELP
(A) Immunofluorescence analyses with antibodies to BRN3a and GFP of cryostat retinal sections from animals electroporated with the GFP
vector. Six animals were sacrificed 15, 25, 50, and 75 days after the intervention. GCL, ganglion cell layer; IPL, inner plexiform layer; INL,
inner nuclear layer; ONL, outer nuclear layer. Scale bars represent 50 mm.
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re-evaluated the video recording to conﬁrm the reliability of the
scoring system. Scores obtained from half of the control rats
shown in Figure 5A represented a subgroup of the animals just be-
fore in vivo ELP; these animals were subjected to the optomotor
test before sacriﬁce, and their scores are shown in Figures 5C
and 5D.
Statistical Analyses
Values are expressed asmeans5 standard error of themean (SEM).
Data were compared via the Student’s t test for all kinds of counts.
p values of <0.05 were regarded as signiﬁcant, and those <0.01
were regarded as highly signiﬁcant.
Results
Gene Transfer into RGCs by In Vivo Electroporation
Gene introduction efﬁcacy by in vivo ELP17 was evaluated
in RGCs over time. Six animals electroporated with the
gene encoding the green ﬂuorescent protein (hrGFP) under
the control of the human cytomegalovirus promoter were
sacriﬁced 15, 25, 50, and 75 days after in vivo ELP. To eval-
uate the number of RGCs expressing the GFP, we immuno-
stained cryostat sections of retinas with GFP and BRN3a
antibodies. BRN3a encodes a neuron transcription factor
exclusively expressed in RGCs.24 RGC-positives for both
antibodies were counted in four independent retinal sec-
tions per animal. GFP immunostaining was mainly appre-
ciated in the ganglion cell layer (GCL), indicating that
DNA injection in the vitreous body and subsequent
in vivo ELP effectively delivered DNA to the GCL. Some
GFP-positive cells, possibly amacrine cells, were also seen
in the inner nuclear layer (INL) (Figure 1A). The proportion
of GFP-positive cells among the total BRN3a-labeled popu-
lation in the GCL increased over time up to day 50
(Figure 1B). At 25 and 50 days, more than 70% of the cell
population that immunostained with the Brn3A antibody
were also immunoreactive to the GFP antibody. When an-
imals were sacriﬁced 75 days after in vivo ELP, the longest
period examined, GFP expression was strongly reduced;
indeed, only 12% of BRN3a-immunostained RGC somas
remained GFP positive, indicating the nucleus-degradation
of DNA molecules from the vector at that time point.
Light-microscopic observations of retinal sections revealedneither structural impairments nor inﬂammatory re-
sponses at different times after in vivo ELP (data not
shown). Additionally, the overall number of RGCs in ele-
troporated eyes was not statistically different from that in
controls; according to Student’s t test p values were 0.66,
0.83, 0.67, and 0.97 for animals sacriﬁced 15, 25, 50, and
75 days after ELP (Figure 1B). Because in vivo ELP was an
effective and sustainable method for introducing DNA
into RGCs without noticeable cell damage, we used it to
create an animal model of LHON disease by introducing
vectors leading to the optimized allotopic expression of
the human mitochondrial ND4 gene, as recently re-
ported.15,16 By in vitro mutagenesis of the wild-type engi-
neered human ND4 gene, we obtained a nuclear version
harboring the G11778A substitution. Both wild-type ND4
and its mutant counterpart were combined with the two
mRNA targeting sequences of human COX10, which
ensures the efﬁcient sorting of the mRNAs to the mito-
chondrial surface.15,16 To estimate the efﬁciency of our
constructions on directing the expression of nuclearly en-
coded ND4 genes, we performed in vivo ELP in one eye of
18 animals with GFP, mutant, or wild-type ND4. Animals
were sacriﬁced 25 days later, and total RNAs were obtained
from puriﬁed RGCs. Steady-state levels of hybrid mRNAs
(COX10-ND4) were compared to endogenous ND4 and
b-actin mRNAs by semiquantitative RT-PCRs after 25, 30,
and 35 cycles of ampliﬁcation. The quantiﬁcation of sig-
nals obtained indicated that levels of transgene ND4 and
b-actin transcripts were similar, and almost 3-fold lower
than endogenous ND4 mRNA in RGCs expressing either
wild-type or mutant ND4 (Figure 1C, upper panel). More-
over, steady-state levels of hybrid mRNAs were comparable
in cells allotopically expressing either of the ND4 genes.
We further examined the relative amounts of COX10-
ND4 mRNAs and two nuclearly transcribed mRNAs IGF1
(encoding the insulin-like growth factor) and SDH1 (en-
coding a mitochondrial protein of respiratory chain com-
plex II), as well as the mitochondrially transcribed ATP6
gene (which encodes a subunit of respiratory chain com-
plex V). As expected, RGCs electroporated with GFP vector
did not show any signal when primers for hybrid ND4
mRNA were used. The relative levels of both ATP6 and
ND4 genes transcribed from mtDNA were comparable in(B) Numerical evaluation of data presented in (A). Four independent sections per animal were counted for BRN3a-positive cells in controls
(RGC-GFP); in electroporated animals the number of cells labeled with both BRN3a and GFP antibodies was estimated (RGC-GFPþ). Mean5
SEM for six control rats and animals euthanized 15, 25, 50, or 75 days after in vivo ELP are shown.
(C) The steady-state levels of endogenous and hybrid ND4 mRNAs were determined in purified RGCs from animals subjected to in vivo ELP
with either mutant ND4 (RGCs þ G11778A-ND4), wild-type ND4 (RGCs þ WT-ND4), or the empty vector (RGCs þ GFP) by RT-PCR. Upper
panel: Semiquantitative estimations were made after 25, 30, and 35 cycles of PCR amplification with 60 mg of RNA as a starting material.
Densitometric analyses were performed with signals revealed by electrophoresis (1/10 of the RT-PCR reaction) for three independent RNA
extractions and two RT-PCRs per RNA. Bar graphs represented ratios5 SEM of either endogenous mtDNA ND4 (mtND4) or b-actin signals
to COX10-ND4 signal obtained with RNA purified from RGCs expressing either mutant (G11778A-ND4) or wild-type ND4 (WT-ND4). Bottom
panel: Relative amounts of b-actin, COX10-ND4, IGF1, SDH1, mtND4 andmtATP6mRNAs were evaluated after 30 cycles of PCR amplification
of the reverse-transcribed products from 60 mg of RNAs obtained from RGCs expressing either mutant ND4 (RGCs þ G11778A-ND4), wild-
type ND4 (RGCsþ WT-ND4), or the empty vector (RGCs þ GFP). Bar graphs represent ratios5 SEM of COX10-ND4, IGF1, SDH1, mtND4, and
mtATP6 signals to b-actin signal. RT-PCR experiments were performed twice for three independent RNA extractions.
Specific oligonucleotides used for each gene are summarized in Table S1.
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Figure 2. Ex Vivo Properties of RGCs Isolated from Electroporated Eyes
(A) RGCs were purified as previously described.20 After 10 days of culture, cells were visualized by indirect immunofluorescence with an-
tibodies against NF200 or ATP synthase a-subunit. RGCs were labeled essentially within their neurites; a clear difference in their lengths
was noticed between cells purified from eyes expressing mutant ND4 (G11778A-ND4) and those expressing wild-type ND4. The merged
image of immunofluorescence revealed a significant colocalization of both NF200 and ATP synthase-a signals in cells examined. The scale
bar represents 25 mm (magnification of 2003). A high-power view (magnification of 6303) featuring one of the cells immunolabeled with
the antibodies is also presented for each condition; scale bars represent 8 mm.
(B) The subcellular localization of the allotopically expressed ND4 proteins was examined by indirect immunofluorescence with an anti-
body against the FLAG epitope (ND4-FLAG) in RGCs cultured for 10 days, and this was compared to signal obtained with the antibody
against NF200. The merged image of immunofluorescence shows a significant colocalization of the fusion ND4 and NF200 proteins in
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all cells evaluated and approximately 3-fold higher than
either one of the nuclearly transcribed mRNAs tested (Fig-
ure 1C, bottom panel). Even though we are aware that
COX10-ND4 mRNA abundance would be underestimated
given that not all of the RGCs analyzed expressed the
transgenes (Figures 1A and 1B), these experiments allowed
us to conclude that both engineered human ND4 genes
introduced into RGCs by in vivo ELP were efﬁciently tran-
scribed. Therefore, we will be able to measure the impact
on RGC function of the corresponding polypeptides.
Ex Vivo Properties of RGCs Isolated
from Electroporated Eyes
In the few LHON cases that have been studied histopatho-
logically, a drastic loss of RGC and nerve ﬁber layer (NFL)
was the major retinal ﬁnding.25 Therefore, we examined
whether the in vivo expression of mutant ND4 inﬂuenced
RGC survival and neurite outgrowth in primary RGC
cultures. For RGC puriﬁcation, immunopanning was
performed on eyes that expressed, for 25 days, either wild-
type ND4 or its counterpart bearing the G11778A substitu-
tion. The number of viable cells and their ability to develop
neuritic processes were evaluated in six independent exper-
iments, after 10 days of culture in rat retinal cell-condi-
tioned medium.20 We assessed cell survival by counting
RGCs immunolabeled by theNF200 antibody,which recog-
nizes the heavy subunit of intermediate neuroﬁlaments;
this subunit is speciﬁcally found in RGCs of several mam-
malian species.26,27 In vivo expression of mutant ND4 led
to a consistent and signiﬁcant decrease in the number of
NF200-positive cells in culture as compared to in vivo ex-
pression ofwild-typeND4 (865 9.6 and 2375 13.3 respec-
tively, an approximate 3-fold decrease). The difference was
signiﬁcant according to a Student’s t test (p value¼0.00016;
n¼ 6). Notably, the majority of RGCs in cultures from eyes
expressing wild-type ND4 possessed multiple (three to six)
processes that extended for many cell-body diameters and
were often branched. Neurite lengths occasionally mea-
sured up to 500 mm. Interestingly, the neuritic processes
fromproximal cells tended to fuse as illustrated in Figure 2A
(wild-typeND4). Immunoreactivity obtainedwith the anti-
body against the mitochondrial ATP synthase a-subunit
was similar to the one observed with the NF200, indicating
that mitochondria were distributed along the neuritic
processes and in the cytosol (Figure 2A). Cultured RGCs
from eyes electroporated with mutant ND4 were scarceand generally had no more than two short neurites.
NF200-positive somas devoid of processes and neurites
not associated with cell bodies were often seen, suggesting
that by the end of the experiment cells had died (Figures 2A
and 2B, G11778A-ND4 arrows). Counting the number of
NF-200-positive cells presenting at least oneprocess that ex-
tended for around four soma diameters showed a clear dif-
ference between RGCs under the two conditions examined
(175 7.5 and 2015 10.3 formutantND4 and its wild-type
counterpart, respectively). Fewer than 20% of RGCs puri-
ﬁed from eyes electroporated with mutant ND4 developed
long neurites, whereas approximately 85% of RGCs from
eyes electroporatedwithwild-typeND4did so. RGC expres-
sion of ND4 genes 35 days after the electroinduction was
evaluatedwith FLAG antibody (Figure 2B).Most of the cells
puriﬁed from eyes electroporated with either version of the
ND4 gene were labeled with the antibody. This immunore-
activity was consistently found in both cell bodies and
neurites independently of their length. There was a clear
colocalization of NF200 and FLAG labeling. Interestingly,
within the processes FLAG antibody revealed distinct clus-
ters, suggesting that ND4 fusion proteins could be asym-
metrically distributed along them. Additionally, Figure 2C
illustrates that of the RGCs isolated from eyes electropo-
rated with mutant ND4, those that were able to develop
long neuritic processes did not express the human ND4
gene. This result indicated a correlationbetweenmitochon-
drial accumulation of the mutated ND4 protein in RGCs
and their inability to grow neuritic processes in culture.
Expression of Mutant ND4 Had a Deleterious
Effect on RGCs In Vivo
To conﬁrm in vivo expression of ND4 genes, we examined
cryostat retinal sections from animals sacriﬁced 25 days
after in vivo ELP by immunochemistry with FLAG,
NF200, GFP, and BRN3a antibodies. Cells in the GCL
showed strong immunoreactivity to anti-FLAG in the cyto-
plasm, especially around the nuclei and along the axons
(Figure 3A, ND4-FLAG). Figure 3A also illustrates a signiﬁ-
cant colocalization between FLAG and NF200 antibodies,
as observed in cultured RGCs (Figure 2). Retinal sections
immunolabeled with GFP and BRN3a antibodies consis-
tently showed a diminution of BRN3a-postive cells in
eyes electroinduced with mutant ND4 (Figure 3B,
G11778A-ND4). To evaluate this effect quantitatively, we
counted BRN3a-positive cells in 24 animals in which onethe cytosol and along neuritic processes. The scale bar corresponds to 25 mm (magnification of 2003). A high-power view (magnification
of 6303) featuring immunolabeled cells is also presented for each condition; scale bars represent 8 mm.
In both (A) and (B), arrows indicate either RGC somas lacking neuritic extensions or isolated neurites that were not associated with RGC
nuclei. These signals have been often found in eyes electroporated with mutant ND4, indicating its deleterious effect on RGC survival
ex vivo.
(C) A retinal ganglion cell purified from eyes electroporated with mutant ND4, which developed long neuritic processes, is shown. This RGC
did not immunostain with anti-FLAG antibody, indicating that it did not express mutant ND4. The bar corresponds to 25 mm (magnifi-
cation of 2003). In the bottom of the image, a RGC with two short neurites is also shown, this cell was immunolabeled with anti-FLAG
antibody, indicating the expression of mutant ND4. Scale bars represent 25 mm. A high-power view (magnification of 6303) featuring the
two RGCs immunolabeled with the antibodies is also presented; scale bars represent 8 mm.
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Figure 3. In Vivo Expression of Mutant
ND4
(A) Immunofluorescence analyses with
antibodies against the NF200 protein and
the FLAG epitope were performed on cryo-
stat retinal sections from animals electro-
porated with either mutant (G11778A
ND4) or the wild-type ND4 gene and sacri-
ficed 25 days later. The image illustrates
cells strongly immunostained with NF200
in the GCL, indicating that they were
RGCs. The signal was essentially visualized
along cell axons and around the nuclear
envelops but was excluded from the nu-
cleus (DAPI). As we observed in cultured
RGCs (Figure 2) ND4 fusion proteins pre-
sented the same subcellular distribution
than NF200, illustrated by the significant
colocalization of both Flag and NF200 sig-
nals (MERGED). A magnification of 6303 is
shown; the scale bar corresponds to 10 mm.
(B) The effect of in vivo ELP on RGC viabil-
ity was assessed by immunostaining with
BRN3a for labeling ganglion cell nuclei
and with GFP for labeling electroinduced
cells. The number of RGC-positive cells
were estimated with merged images of
BRN3a and DAPI stainings. It clearly ap-
peared that the number of RGCs was
strongly reduced when the eyes expressed
mutant ND4 (G11778A ND4) in comparison
to when eyes were electroporated with
wild-type ND4. Retinal sections shown cor-
respond to animals sacrificed 25 days after
in vivo ELP. Scale bars represent 50 mm
(magnification of 2003). GCL, ganglion
cell layer; IPL, inner plexiform layer; INL,
inner nuclear layer; and ONL, outer nuclear
layer.
(C) Retinas were assessed for TUNEL label-
ing after in vivo ELP with either mutant
(G11778A ND4) or wild-type ND4 vector.
The frequency of TUNEL-positive cells was
greater in the GCL of retinas expressing
mutant ND4 (G11778A ND4) than in retinas expressing its wild-type counterpart (wild-type ND4). The intensity of staining and the num-
ber of cells displaying advanced apoptotic features (arrows) was increased in retinas expressing mutant ND4. Some cells showed prefer-
ential staining of chromatin in the proximity of the nuclear envelop, a feature of early-stage apoptosis (arrows). Rarely, few TUNEL-pos-
itive cells were evidenced in the INL of animals electroporated with mutant ND4, suggesting that amacrine cells expressing mutant ND4
could undergo apoptosis. Scale bars represent 25 mm (magnification of 4003). GCL, ganglion cell layer; IPL, inner plexiform layer; INL,
inner nuclear layer; and ONL, outer nuclear layer.eye was electroporated with mutant ND4 and compared
this number to counts from (i) 11 animals electroporated
in one eye with wild-type ND4 and (ii) 14 animals electro-
porated in one eye with the empty vector (GFP). Table 1
shows the mean number of BRN3a-positive cells for four
independent retinal sections per animal in comparison
to the total amount of DAPI-stained nuclei in the GCL.
The number of BRN3a-positive cells in retinas expressing
mutant ND4 was approximately 30% lower than in retinas
expressing either wild-type ND4 or GFP. This result was380 The American Journal of Human Genetics 83, 373–387, Septemhighly signiﬁcant according to a Student’s t test (p ¼ 1.6 3
1005 for G11778A-ND4/WT-ND4 groups and p ¼ 3.8 3
1005 for G11778A-ND4/GFP groups). Moreover, the
RGC number diminution was accompanied by a 13%
decrease in DAPI-stained cells in the GCL (Table 1). This
decrease was also signiﬁcant: p ¼ 0.04 for G11778A-ND4/
WT-ND4 groups and p ¼ 0.05 for G11778A-ND4/GFP
groups. Importantly, the wild-type ND4 gene transduction
did not compromise RGC viability. Indeed, there was sig-
niﬁcant difference neither in the number of RGCs nor inber 12, 2008
the overall amount of cells in the GCL when the eyes
were electroporated with GFP or wild-type-ND4 vectors
(Table 1, p ¼ 0.36). Thus, the negative impact on RGC
survival is the direct consequence of mutant ND4 allotopic
expression.
Next, we performed a TUNEL assay on retinal sections
from six animals 25 days after in vivo ELP with either
wild-type or mutant ND4 vectors (Figure 3C). Eyes electro-
porated with the wild-type gene were almost TUNEL-nega-
tive; out of four independent retinal sections per animal
the average number of positive cells was 1.55 0.8. In con-
trast, the fraction of TUNEL-positive cells in the GCL was
12-fold higher (18 5 5) in eyes that were electroporated
with mutant ND4, and TUNEL labeling in the GCL was
consistently observed (Figure 3C). This difference was sig-
niﬁcant according to a Student’s t test (p ¼ 0.0055; n ¼ 6).
Interestingly, the TUNEL-positive cells had a diverse range
of morphology. Some cells displayed densely stained
nuclei, whereas others showed preferential staining of
chromatin close to the nuclear periphery; such staining
could indicate an early stage of apoptosis (Figure 3C,
arrows). The above results indicate that the expression of
mutant ND4 induced neuronal cell death in the GCL,
consistent with the signiﬁcant reduction of RGC counts
in retinal sections (Table 1).
RGC Loss Induced by Mutant ND4Was Rescued by
Introduction of the Wild-Type Gene
Because in vivo transgene expression was stable for up to
50 days, we attempted to prevent RGC loss in animals
that had expressed mutant ND4 for 14 days by performing
a second ELP with its wild-type counterpart. Then, animals
were examined 31 days later (day 45), when it was ex-
pected that a large number of RGCs would simultaneously
express both versions of ND4. First, we measured RGC loss
at 14 and 48 days after in vivo ELP. Retinas from ﬁve ani-
mals sacriﬁced 14 days after ELP with mutant ND4 gene
did not show signiﬁcant differences in the number of
RGCs (Table 2, p ¼ 0.45). The number of RGCs was also
determined in eight animals after 48 days of mutant ND4
expression and in 23 animals that expressed wild-type
ND4 for 48 days. In those animals that expressed mutant
ND4 animals for 48 days, an approximate 38% decrease
in RGC counts was observed in comparison to when
Table 1. Overall Number of RGCs in Retinal Sections of
Electroporated Eyes after 25 Days of Transgene Expression
GFP
n ¼ 14
G11778A-ND4
n ¼ 24
Wild-Type ND4
n ¼ 11
Overall number of RGCs 2925 21 1975 13 2745 14
Total number of cells in
the GCL
10865 52 9665 51 11185 68
RGCs were counted after immunolabeling with BRN3a antibody. The RGC and
total cell numbers presented in the table represent the means 5 SEM
obtained after all of the BRN3a and DAPI-positive cells in the GCL were
counted in four independent retinal sections per animal.The Americanwild-type ND4 was expressed. This difference was highly
signiﬁcant according to a Student’s t test (p ¼ 3.9 3 108).
Next, eyes from 18 animals were subjected to a ﬁrst ELP
with mutant ND4. After 2 weeks, eyes expressing mutant
ND4 were subjected to a second ELP with the wild-type
gene. Thirty-one days later, the animals were sacriﬁced,
and RGCs were counted. The transduction of wild-type
ND4 in RGCs at day 14 signiﬁcantly prevented RGC loss
in vivo; total numbers of RGCs were not statistically differ-
ent between eyes electroporated twice and rat eyes that re-
ceived only wild-type ND4 (Table 2, p ¼ 0.19). Moreover,
the highly signiﬁcant difference between RGC numbers
in these animals relative to animals that expressed mutant
ND4 for 48 days (Table 2; p ¼ 2 3 106) demonstrated the
beneﬁcial effect of wild-type ND4 expression on RGC
survival.
To conﬁrm that the neuroprotection observed was the
direct consequence of wild-type ND4 gene expression, we
subjected eight animals that expressed mutant ND4 for
14 days to a second ELPwith the GFP vector and performed
RGC counts 31 days later. It was clear that GFP expression
did not protect RGCs because their number was reduced by
almost 40% (Table 2). The total number of cells in the GCL,
estimated by DAPI labeling, in animals electroporated with
the mutant ND4 genes or mutant ND4 þ GFP appeared
diminished in comparison to cells counted in eyes electro-
porated with wild-type ND4. However, the decrease was
statistically signiﬁcant only for eyes electroporated with
both mutant ND4 and GFP (Table 2, p ¼ 0.02). There was
no signiﬁcant difference between the overall number of
cells in the GCL of animals expressing mutant ND4 and
the number in animals expressing both mutant ND4 and
GFP (p ¼ 0.27), arguing against the possibility that the sec-
ond round of ELP with the GFP damaged the GCL. Further-
more, total cell number in the GCL was quite similar in
eyes electroporated with wild-type ND4 and eyes electro-
porated with both mutant and wild-type ND4 (Table 2,
p ¼ 0.8), thus indicating that treatment at day 14 with
wild-type ND4 halted cell loss in the GCL.
For examination of a possible association between RGC
soma loss estimated by immunostaining for BRN3a (Tables
1 and 2) and changes in RGC intraretinal axons, retinal
whole mounts from controls or animals subjected to
in vivo ELP were processed for immunohistochemistry
with NF200 (Figure 4). It clearly appeared that very few
axon proﬁles were visible in retinas in which in vivo ELP
was performed with mutant ND4 (Figure 4A); conversely,
the number of axons stained with NF200 was higher and
comparable in retinas from eyes electroporated with either
wild-type ND4 or GFP (Figure 4A). Whole-mount retinas
from eyes in which a second ELP was performed with
either wild-type ND4 or GFP were immunostained with
NF200. Remarkably, the number of axons stained by
NF200 was consistently higher when ELP was performed
with wild-type ND4 than when eyes were electroporated
with GFP. Indeed, no noticeable difference in the staining
was detected between whole-mount retinas from controlJournal of Human Genetics 83, 373–387, September 12, 2008 381
Table 2. Overall Number of RGCs in Retinal Sections of Electroporated Eyes
Animals Sacrificed 14 Days after ELP Animals Sacrificed 48 Days after a Unique ELP Animals Sacrificed 45 Days after the First ELP
G11778A-ND4
n ¼ 5
Wild-type ND4
n ¼ 5
G11778A-ND4
n ¼ 8
Wild-type ND4
n ¼ 23
G11778A-ND4 þ
Wild-type ND4 n ¼ 18
G11778A-ND4 þ
GFP vector n ¼ 8
RGC number 2925 12 3055 12 1835 10 2975 10 2765 10 1785 10
Total cell number 10005 35 10585 46 9775 49 10335 31 10205 41 8955 42
RGCs were counted after immunolabeling with BRN3a antibody. DAPI staining allowed estimation of total nuclei in the GCL. Five animals were sacrificed 14
days after the electroinduction. Eight retinas were evaluated after long-term expression of mutant ND4, and 23 retinas were evaluated after long-term
expression of its wild-type counterpart (48 days). Eighteen animals were subjected to two ELPs and sacrificed 31 days after the second intervention. First,
they expressed for 14 days mutant ND4, and the same eye received its wild-type counterpart. Eight additional rats were subjected to two ELPs, the first one
with mutant ND4 and 14 days later with the GFP vector. The RGC and total cell numbers presented in the table represent the means5 SEM obtained after all
of the BRN3a and DAPI-positive cells in the GCL were counted for four independent retinal sections per animal.eyes and those from eyes electroporated ﬁrst with mutant
ND4 and then with its wild-type counterpart (Figure 4B).
These data indicated that RGC axon degeneration was
prevented in animals subjected to a second ELP with
wild-type ND4.
Functional Assessment of Visual Responses in Animals
Expressing Mutant ND4
The functional impact of RGC loss due to the expression of
mutant ND4 was assessed by optomotor head-tracking ex-
periments in 12-week-old pigmented Long Evans rats.21,23
Tracking capability was examined in both clockwise and
counterclockwise drum rotations at three spatial frequen-
cies. Because only temporal-to-nasal motion is effective
through each eye, clockwise movement will drive tracking
through the left eye, whereas counterclockwise motion
will activate the right eye.23 Therefore, we were able to
independently assess vision of the two animal eyes.
Ten control rats, eight animals that had expressed for
25 days in their right eyes wild-type ND4, and ten animals
that had expressed mutant ND4 in the same eye for the
same period were subjected to the test. Figure 5A shows
no signiﬁcant difference between clockwise and counter-
clockwise responses in control animals for any of the spa-
tial frequencies monitored (Student’s t test; p ¼ 0.97, 0.23,
and 0.42 for 0.125, 0.25, and 0.5 cyc/deg, respectively). An-
imals expressing the wild-type ND4 gene mostly presented
head-tracking scores of a magnitude similar to that of
control animals (Figure 5B), and as in controls, scores
were not signiﬁcantly different for the clockwise and coun-
terclockwise drum rotations (Student’s t test; p ¼ 0.6, 0.92,
and 0.22 for 0.125, 0.25, and 0.5 cyc/deg, respectively). An-
imals expressing mutant ND4 performed signiﬁcantly
worse at all frequencies for the counterclockwise drum
rotation but performed similarly to controls and animals
expressing wild-type ND4 in the clockwise drum rotation
(Figure 5C). The decline in visual performance of these an-
imals, scored for the counterclockwise drum rotation, was
statistically different for each spatial frequency of visual
stimuli (Student’s t test; p ¼ 0.0075, 0.011, and 0.0065
for 0.125, 0.25, and 0.5 cyc/deg, respectively). As expected,
the optomotor responses for the counterclockwise rotation
were signiﬁcantly different in eyes electroporated with382 The American Journal of Human Genetics 83, 373–387, Septemmutant ND4 than in untreated eyes or in eyes electropo-
rated with wild-type ND4. For instance, at the spatial fre-
quency of 0.125 cyc/deg, comparisons of the G11778A-
ND4/control group and theG11778A-ND4/WT-ND4 group
gave p values of 0.015 and 0.018, respectively. To evaluate
whether the neuroprotection achieved by the second ELP
with wild-type ND4 (Table 2 and Figure 4) led to visual
function beneﬁts, we monitored head-tracking perfor-
mance in ten rats subjected to a second ELP with wild-
type ND4 14 days after the ﬁrst intervention in their right
eyes with mutant ND4. The second ELP prevented the loss
of visual function, and indeed, counterclockwise scores for
the three frequencies examined were higher than those
measured in animals in which only mutant ND4 was
expressed (Figure 5D). For instance, the acuity score mea-
sured in these rats was 77% of that measured for the
accompanying untreated eyes for the spatial frequency of
0.125 cyc/deg for the counterclockwise drum rotation.
This was signiﬁcantly better (p ¼ 0.00032) than tracking
scores for animals electroporated with mutant ND4
(Figure 5C; 17.8% of that measured in the accompanying
untreated eyes).
To further conﬁrm the deleterious effect of mutant ND4
expression on visual function, we performed optomotor
head-tracking experiments in four animals that expressed
mutantND4 in their left instead of right eyes (Table 3). An-
imals did not exhibit much tracking at any frequency with
clockwise stimulus motion, implying poor visual acuity in
their left eyes. Conversely, when the motion was reversed,
tracking was normal, and scores recorded for these animals
were similar to those for control rats or animals electropo-
rated with wild-typeND4 (Figure 5A and 5B). Thus, a direct
link exists between mutant ND4 expression and decreased
visual capabilities independently of which eye was treated.
Moreover, four animals subjected to two ELPs in their left
eyes showed a clear improvement in their visual responses
for clockwise drum rotation; indeed, in contrast to animals
subjected to a unique ELP, these animals tracked signiﬁ-
cantly better in all frequencies monitored for the clockwise
stimulus motion (Table 3).
Therefore, expression of wild-type ND4 unambiguously
preserved visual function in animals that expressed mu-
tant ND4 for 14 days, and this was certainly correlated tober 12, 2008
Figure 4. NF200-Labeled Axons in
Whole-Mmount Retinas
(A) Immunostaining with NF200 in whole-
mount retinas from animals subjected to
a unique ELP clearly showed many fewer
NF200-positive axons when animals were
electroinduced with mutant ND4
(G11778A-ND4) than when both retinas
expressed either the empty vector (GFP)
or the wild-type gene (WT-ND4).
(B) Retinal flat-mount labeled with NF200
from a control animal (13 weeks old) was
compared to the labeling obtained in
animals electroporated twice. It clearly
appeared that when the second ELP was
performed with wild-type ND4 there was
good axon preservation (G11778A-ND4 þ
WT-ND4), whereas relatively poor preserva-
tion was seen in the GFP-treated retina
(G11778A-ND4 þ GFP), similar to the one
observed when a unique ELP was performed
with mutant ND4 (A). A magnification of
2003 is shown. ON, optic nerve.the prevention of RGC soma and intraretinal-axon loss
demonstrated in vivo after the second ELP (Table 2 and
Figure 4).
Discussion
Because of the multiplicity of mitochondrial functions,
ranging from intermediate metabolism to energy produc-
tion and apoptosis, there exist many potential avenues
whereby damaged mitochondria can compromise cell
survival. Extensive research efforts aimed at deciphering
themolecular basis of mitochondria implication in human
diseases are currently underway worldwide. However, the
impact of these efforts on the identiﬁcation of valuable
remedies is very limited, and we are still unable to treat
mitochondrial diseases.5 A recent review has evaluated
randomized and quasi-randomized trials comparing phar-
macological (vitamins) and nonpharmacological (food
supplements) approaches as well as physical training in
patients with mitochondrial disorders. The authors con-
cluded that there is currently no clear evidence supporting
the use of any intervention inmitochondrial disorders and
that further research is needed to establish the role of
a wide range of therapeutic approaches.28 Within this con-
text, mtDNA-related disorders encompass an increasing
number of clinical pictures due to more than 300 different
provisional or conﬁrmed pathogenic changes inmtDNA.29
Gene therapy for mtDNA-related diseases presents four
major problems: (1) the nature of an efﬁcient protocol
that takes into account the unique properties of mtDNA
(heteroplasmy, polyplasmy) and the hydrophobic nature
of the 13 proteins encoded by the organelle genome; (2)
the lack of suitable animal models for testing and validat-
ing new therapies; (3) the inability to manipulate themito-The Americanchondrial genome inside the organelle of living cells; (4) as
for any Mendelian disorder, the choice of vectors, delivery
method, and dose/toxicity studies.
Vision impairment is a prevalent feature in mitochon-
drial diseases; indeed, retina cells contain a large number
of mitochondria, reﬂecting their high energy require-
ments.30 Moreover, mitochondrial dysfunction may con-
tribute to changes in macular function observed in aging
and age-related macular degeneration.31 Because the eye
has a delimited and highly isolated structure, immunopri-
vilege, and accessibility, it is a particularly promising organ
with respect to gene therapy.32 Hence, two groups recently
described the ﬁrst results of clinical trials investigating the
short-term safety and preliminary efﬁcacy of gene therapy
for Leber’s congenital amaurosis type II (LCA, [MIM
204100]), a severe early-onset retinal degeneration due to
mutations in the RPE65 gene (MIM þ180069).33 The pa-
tients were enrolled in trials of recombinant adeno-associ-
ated virus (rAAV) delivery of the human RPE65 [MIM þ
180069]. The data suggested that in the short-term, the
procedure is safe and efﬁcient and provided the founda-
tion for gene therapy approaches to the treatment of
LCA and possibly other forms of retinal degeneration.34,35
Our main objective is to develop a gene therapy that
could be both preventive and curative for optic neuropa-
thies due to mitochondrial dysfunction. In this pursuit,
we focused on the LHON disease due to known mutations
inmtDNA.Disease onset in themajority of cases is between
15 and 35 years of age, but with the availability of the
molecular diagnosis, early or late cases are increasingly re-
ported.10,36 LHON typically manifests as acute or subacute
bilateral loss of vision. Visual loss often occurs asynchro-
nously over the course of several weeks to months.10,37
Some patients continue in a ‘‘chronic’’ state characterized
by a low-grade degenerative process that may consistentlyJournal of Human Genetics 83, 373–387, September 12, 2008 383
Figure 5. Assessment of Visual Func-
tion via Optomotor Tests of Long Evans
Rats
(A) Head-tracking responses of ten con-
trols (8 and 12 weeks old) compared with
rats electroporated in their right eyes
with the wild-type ND4 gene (B). The three
grating frequencies of 0.125, 0.25, and 0.5
cyc/deg are shown in both clockwise (ar-
rows revolving in clockwise direction) and
counterclockwise (arrows revolving in
counterclockwise direction) directions of
motion. Visual thresholds in these animals
did not depend on the direction of rotation
given that no significant difference was
measured in the three grating frequencies
monitored. Moreover, the scores were com-
parable in all the rats assessed, indicating
that electroporation with wild-type ND4
(B) did not compromise visual acuity.
(C) Optomotor tracking in ten animals
subjected to in vivo ELP with mutant
ND4. In vivo ELP in the right eye with
mutant ND4 strongly diminished tracking
when the grating motion was counter-
clockwise but had no effect on clockwise
tracking. According to a Student’s t test,
a significant difference was measured in
the three grating frequencies monitored, indicating a link between mutant ND4 expression and the loss of visual function.
(D) Ten animals were subjected to a second ELP with wild-type ND4 14 days after mutant ND4 expression in their right eyes. Head-tracking
responses in the counterclockwise motion were significantly better in these animals than in those subjected to a single ELP with mutant
ND4. For instance, comparative analyses of means tracking in the 0.125 cyc/deg grating frequency of clockwise and counterclockwise
responses were not statically different according to a Student’s t test (p ¼ 0.1).
For animals subjected to ELP, all the assessments were performed 25 and 35 days after the intervention, and values presented are the
means 5 SEM of these two assessments.worsen the residual vision over the years.37 Hence, the
acutely symptomatic LHONpatient withmonocular vision
loss provides aunique clinical situation inwhich it becomes
possible not only to test a therapeutic agent during the
critical window before vision is lost in the second eye
but also to prevent the progressive worsening of visual
function.
We have developed an approach of gene therapy that
successfully restores OXPHOS dysfunction in preclinical
models for three different mtDNA gene mutations. Our
optimized allotopic expression vectors allowed the replace-
ment of defective proteins in ﬁbroblasts harboring 100%
of mutated mtDNA molecules in ATP6, ND4, or ND1
genes.15,16 Thus, we have created in these cells a situation
often found in patient tissues, where mutated and wild-
type mtDNAs coexist in various proportions (hetero-
plasmy). It has been clearly demonstrated that the percent-
age of mutated forms contributes to disease expression in
patients and that symptoms only appear above threshold
levels of mutant mtDNA molecules.1,3 With our approach,
we have forced the system into reverse by expressing wild-
type mitochondrial genes to push the proportion of the
mutant form below the threshold for pathology. The key
to our approach has been the inclusion in the expression384 The American Journal of Human Genetics 83, 373–387, Septemvectors of the COX10-30 UTR, which allows the sorting to
the mitochondrial surface of mRNAs and maximizes un-
equivocally mitochondrial translocation of these highly
hydrophobic proteins.15,16 Henceforth, this innovation
makes feasible the prospect of gene therapy for mtDNA-
related diseases and circumvents the limitations encoun-
tered to date.13,14 Recently, Qi and colleagues showed
that the allotopic expression of a nuclear version of the
mutant ND4 gene in mouse eyes led to RGC and optic-
nerve degeneration, and these mice can be used for testing
the effectiveness of treatments for LHON.38 Nevertheless,
their approach could encounter the limitation of the
inefﬁcient mitochondrial import of the hydrophobic
ND4 protein because the corresponding mRNA was not
sorted to the mitochondrial surface. Transgene expression
could thus become potentially toxic for mouse retina over
time, preventing the generation of a robust mouse model
of LHON. In our study, the highest effectiveness for mito-
chondrial dysfunction rescue was achieved when both the
MTS and 30 UTR of COX10 were combined with wild-type
genes.15 These ﬁndings conﬁrmed our previous data in
HeLa cells: The amount of fully mitochondrially translo-
cated ATP6 protein was around 2-fold higher when the
nuclearly recoded ATP6 gene was associated with bothber 12, 2008
Table 3. Optomotor Tests of Animals Electroporated in Their Left Eyes
Animals Electroporated Once in Their
Left Eyes with G11778A-ND4 n ¼ 4
Animals Electroporated Twice in Their Left Eyes
with G11778A-ND4 þ Wild-Type ND4 n ¼ 4
Gratings frequency
(cycles per degree) 0.125 0.25 0.5 0.125 0.25 0.5
Clockwise 0.835 0.26 1.885 0.46 2.55 1.1 35 0.7 4.55 1.3 7.45 0.8
Counterclockwise 5.55 0.6 6.35 0.85 8.25 0.45 3.75 1 55 1.1 9.65 0.7
Four animals were subjected to ELP with mutant ND4 in their left eyes. A significant distinction between clockwise and counterclockwise tracking perfor-
mances was observed: p ¼ 0.003, 0.009, and 0.01 for gratings 0.125, 0.25, and 0.5 cyc/deg, respectively. Thus, performances were poor at any frequency
for clockwise stimulus motion. An additional group of four rats was subjected to ELP with mutant ND4, and 14 days later a second ELP was performed with
wild-type ND4. For frequencies of 0.125 and 0.25 cyc/deg , there were no significant differences between clockwise and counterclockwise tracking signals
(p¼ 0.72 and 0.33, respectively) in animals subjected to two ELPs. At 0.5 cycles per degree, p¼ 0.04, but clockwise scores were 77% of the value measured
in the counterclockwise rotation, as opposed to 30.5% in rats expressing mutant ND4 only. Values represented in the table are the means5 SEM obtained
for the eight animals subjected to optomotor tests twice.the MTS and 30 UTR of SOD2 [MIM *147460] than when
just the MTS was present in the construct.39 Moreover, Bo-
kori-Brown and Holt attempted to correct mitochondrial
dysfunction in cells expressing the T8993G in ATP6 by us-
ing a nuclearly encoded human ATP6 gene linked to the
MTS of bovine ﬂavoprotein subunit of complex II, SDHL.
They were unsuccessful in that transgene expression was
deleterious overtime and none of the transformed cells
retained the vector two months after transfection. One
hypothesis that could explain these data is that mRNA
sorting to the mitochondrial surface is essential for ensur-
ing the import of its protein inside the organelle. Thus, if
mRNA is translated somewhere else in the cytosol, high
levels of misfolded hydrophobic protein could accumulate
and lead to progressive decline in cell ﬁtness.
In the present study, we were able to create an animal
model resembling LHON disease by taking advantage of
the speciﬁc features of mtDNA genetics regarding hetero-
plasmy and by using our optimized allotopic-expression
approach. Rat retinal ganglion cells (RGCs) that expressed
in vivo the human ND4 gene harboring the deleterious
G11778A mutation carried a heteroplasmy due to the
coexistence of the endogenous wild-type gene and themu-
tant ND4 gene of our vector. Rat and human ND4 proteins
differ by only 39 amino acids out of 459, and their identity
and strong similarity degrees are of 68% and 20%, respec-
tively, indicating that humanND4 proteins could integrate
rat respiratory chain complex I. We performed in vivo elec-
troporation in animal eyes to introduce ND4 transgenes in
RGCs.17 More than 70% of RGCs expressed them for up to
50 days. Semiquantitative RT-PCR analyses performed in
RGC cells puriﬁed from eyes electroporated with either
wild-type or mutant ND4 showed that corresponding
mRNAs were as abundant as b-actin and IGF1 mRNAs,
two nuclearly transcribed molecules. Transgene mRNA
steady-state levels could have been underestimated be-
cause RNAs were puriﬁed from the total RGC population,
in which not all expressed the transgenes. However, we
evaluated the impact of the coexistence of wild-type and
mutant ND4 genes for RGC function and viability in the
experimental model generated. These animals reproducedThe Americanmorphological and functional features of the LHON
pathology. Both the degeneration of RGC somas and the
severe reduction of RGC intraretinal axons reﬂected selec-
tive death of ganglion cells and therefore recapitulated one
of the pathology hallmarks. Ultimately, compromised RGC
function would lead to optic-nerve atrophy and central
vision loss as described in patients suffering from LHON.
Remarkably, we were able to measure a signiﬁcant decline
of visual performance in animals expressing mutant ND4;
this decline resembled devastating and sudden visual loss
in young adulthood. Moreover, the deleterious impact of
the allotopically expressed mutant ND4 on RGCs was
clearly demonstrated ex vivo; both RGC survival and abil-
ity to outgrowth neuritic processes were compromised.
The deleterious consequences of mutant ND4 expression
for RGC survival were examined in a large number of
animals: 24 and eight animals that expressed the transgene
for 25 and 48 days, respectively. RGC counts undertaken
in these animals revealed a signiﬁcant 30% and 38%
decrease, respectively, when these animals were compared
to 12 age-matched controls, 34 animals electroporated
with wild-type ND4, or 14 animals electroporated with
the GFP vector. Hence, RGC injury due to mutant ND4
expression was more severe when animals were sacriﬁced
48 days after in vivo ELP than when they were sacriﬁced
at day 25. These data indicated that human ND4 protein
was imported into mitochondria of RGCs and perturbed
its function, either by a direct competition with the endog-
enous protein or by an impairment of respiratory chain
complex activity and/or assembly. Unfortunately, it will
be extremely difﬁcult to determine whichmechanism is re-
sponsible of our ﬁndings at the molecular level. Indeed,
a very large number of rat RGCs are required for respiratory
chain complex activity measurements or Blue Native Elec-
trophoresis,14 which would provide compelling evidence
of effective mitochondrial import and assembly of allo-
topically expressed gene product in respiratory chain
complex I. Nevertheless, the strong correlation between
mutant ND4 expression and impaired visual function
encouraged us to pursue the exploration of this experi-
mental model.Journal of Human Genetics 83, 373–387, September 12, 2008 385
Because in vivo ELP led to stable transgene expression for
up to 50 days and, most importantly, because mutant ND4
expression was harmless during the ﬁrst 14 days, we per-
formed a second intervention in animal eyes by using the
wild-typeND4 gene in an attempt to prevent RGC degener-
ation and the loss of visual function. In 18 animals exam-
ined, wild-type ND4 expression signiﬁcantly protected
RGCs, as measured by BRN3a immunostaining and by the
estimation of intraretinal axons in whole-mounted retinas.
These ﬁndings were correlated with the preservation of
visual function in ten of these animals without unwanted
harm or effects on animals or their eyes.The high efﬁciency
of neuroprotection achieved by the second round of ELP
might seem surprising; indeed, no signiﬁcant differences
were found between RGC counts in 18 animals subjected
to two ELPs and 23 animals electroporated with wild-type
ND4 (Table 2, 7% fewer RGCs in animals subjected to two
ELPs). However, the neuroprotection, as determined by
the visual acuity in the injected eyes compared to the ac-
companying untreated eyes of these animals, was of 72%
or 83%when right or left eyes were subjected to two rounds
of ELP. Therefore, visual function was highly preserved, al-
though it did not remain at 100%. One hypothesis that
could explain the impressive prevention of RGC and
visual-function loss achieved by the second ELP with
wild-type ND4 is that cells that were electropermeabilized
during the ﬁrst intervention could be more susceptible to
the second one. Hence, we could obtainmore than an addi-
tive effect for wild-type ND4 treatment, and a very high
proportion of cells expressing mutant ND4 were success-
fully electropermeabilized and received large amounts of
wild-type ND4. Multiple ELPs (up to six within an interval
of a few weeks) have often been applied safely in vivo for
both cancerologic and immunologic purposes and led to
much more efﬁcient results than a single treatment.40,41
In conclusion, we have created a valid animal model of
LHON, and we were able both to prevent animals from
becoming blind and to avoid toxicity. These data represent
a breakthrough for the generation of a treatment aimed at
improving life conditions of patients suffering from optic
neuropathies with a mitochondrial etiology. The next
step toward our goal of clinical trials for preventing
blindness in patients suffering from LHON disease will be
to assess the long-term safety of the optimized allotopic-
expression approach with respect to retinal morphology
and function in large animals by using rAAV-mediated
gene therapy, as recently described.42
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